Research Nester Logo.jpg
Cardiometabolic Drugs Market revenue to exceed USD 72 Billion by 2035, says Research Nester
21 août 2023 06h00 HE | Research Nester
New York, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The global Cardiometabolic Drugs Market size is projected to expand at ~ 6% CAGR between 2023 and 2035. The market is expected to garner a revenue of USD...
Madrigal logo.jpg
Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update
05 août 2021 06h50 HE | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate...
22157.jpg
Global Dyslipidemia Disease Analysis 2020-2027 - Market is Poised to Resume Steady Growth Due to the Introduction of Novel Agents
23 mars 2021 08h03 HE | Research and Markets
Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Dyslipidemia" report has been added to ResearchAndMarkets.com's offering. The report estimates that in 2018, there were...
Madrigal logo.jpg
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
25 févr. 2021 06h50 HE | Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We...
Madrigal logo.jpg
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
13 nov. 2020 06h50 HE | Madrigal Pharmaceuticals, Inc.
Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday,...
Madrigal logo.jpg
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
05 nov. 2020 06h50 HE | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in...
Madrigal logo.jpg
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020
26 août 2020 06h50 HE | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020,...
CMHC Concludes CMHC
CMHC Concludes CMHC West Live Online: Complexities in Cardiometabolic Care.
11 août 2020 12h00 HE | Cardiometabolic Health Congress
Boca Raton, FL, Aug. 11, 2020 (GLOBE NEWSWIRE) -- CMHC Concludes CMHC West Live Online: Complexities in Cardiometabolic Care. CMHC West Live Online: Complexities in Cardiometabolic Care concluded...
Madrigal logo.jpg
Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights
06 août 2020 06h50 HE | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: “The Madrigal team and...
NLA LOGO - USE.png
National Lipid Association Releases Official Scientific Statement on Genetic Testing in Dyslipidemia
10 juil. 2020 12h30 HE | National Lipid Association
JACKSONVILLE, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- The National Lipid Association (NLA) today announced the release of its official scientific statement on the use of genetic testing in the...